German General Merchandise and Department Stores Stock News

Why recent geopolitical tension matters for Rheinmetall shares President Trump’s intervention in Venezuela has sharpened concerns about global security, drawing fresh investor attention to defense contractors. Rheinmetall (XTRA:RHM), closely linked to Europe’s military spending ambitions, recently saw its share price move 7% higher on this backdrop. See our latest analysis for Rheinmetall. For context, Rheinmetall’s recent 1-day share price return of 9.36% and 7-day return of 14.81% come...

New buy-back program puts Deutsche Telekom’s capital return in focus Deutsche Telekom (XTRA:DTE) has launched a fresh share buy-back program for 2026 after completing its 2025 effort, putting the company’s capital return policy and share count trends back in the spotlight for investors. The 2025 program involved repurchasing about 65.4 million shares, around 1.3% of the share capital. For 2026, the Board has approved up to €2b of buy-backs running from January 5 through year end. Management...

While Befesa S.A. ( ETR:BFSA ) might not have the largest market cap around , it saw a decent share price growth of 13...

Key Insights The considerable ownership by retail investors in Redcare Pharmacy indicates that they collectively have a...

As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...

Evotec stock: recent performance snapshot Evotec (XTRA:EVT) has drawn attention after a difficult past 3 months, with the share price showing a negative total return and a similar pattern over the past year, prompting closer scrutiny from investors. See our latest analysis for Evotec. At a share price of €5.51, Evotec has seen short term momentum cool. A 90 day share price return of an 18.71% decline sits alongside a 1 year total shareholder return showing a 35.44% loss. This points to fading...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Low-cost index funds make it easy to achieve average market returns. But across the board there are plenty of stocks...

Most readers would already be aware that Mineralbrunnen Überkingen-Teinach GmbH KGaA's (FRA:MUT) stock increased...

Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really...

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Electronic industry in Germany, you could be...

Remote operations shift puts Siemens Energy (XTRA:ENR) in focus Recent coverage of Siemens Energy’s rollout of Remote Operations Centers, built around its Omnivise software platform, has drawn attention to how the company is centralizing power plant monitoring and predictive maintenance. See our latest analysis for Siemens Energy. The Remote Operations Center rollout arrives after a strong run in the shares, with a 90 day share price return of 21.59% and a very large 3 year total shareholder...

In late December 2025, flatexDEGIRO changed its legal form and that of flatexDEGIRO Bank from a German stock corporation (AG) to a Societas Europaea (SE), while also expanding its Group Management Board and appointing long-serving executive Jens Möbitz as Chief Operating Officer from January 1, 2026. This shift to an SE structure, combined with strengthening operational leadership in banking and IT, signals an effort to streamline governance across the group and prepare for the planned...

Merck KGaA, Darmstadt, Germany recently reported that China’s NMPA has granted Priority Review approval for pimicotinib, a CSF-1R inhibitor, to treat adult patients with symptomatic tenosynovial giant cell tumor where surgery risks functional limitation or relatively severe morbidity. This first Chemical Drug Class 1 approval in China for TGCT, backed by strong Phase 3 MANEUVER data, adds a differentiated rare-disease therapy to Merck KGaA’s healthcare portfolio in a major market. We’ll now...

Without a clear single catalyst in focus, Allianz (XTRA:ALV) is drawing attention as investors reassess its recent share performance, income profile, and business scale across insurance and asset management activities. See our latest analysis for Allianz. Allianz’s share price at €387.7 has had a relatively steady few weeks, with a 30 day share price return of 5.73% and a 90 day share price return of 6.42%, while the 1 year total shareholder return of 35.26% and 3 year total shareholder...

Snowflake partnership sets fresh context for SAP shares SAP (XTRA:SAP) is in focus after announcing a collaboration that links Snowflake’s AI Data Cloud with SAP Business Data Cloud, aiming to simplify data sharing and AI driven insights for enterprise customers. See our latest analysis for SAP. Despite the Snowflake tie up, SAP’s recent 1 day, 7 day and 90 day share price returns of 3.07%, 3.12% and 14.06% declines suggest fading short term momentum. However, its 3 year total shareholder...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

The European market has been buoyed by an improving economic backdrop, with the STOXX Europe 600 Index reaching new highs and closing 2025 with its strongest yearly performance since 2021. Against this optimistic landscape, identifying small-cap stocks that exhibit robust fundamentals and growth potential can be particularly rewarding for investors seeking to capitalize on the region's momentum.

Infineon Technologies AG's ( ETR:IFX ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong...

Key Insights Hannover Rück's significant private companies ownership suggests that the key decisions are influenced by...

Key Insights Aurubis' estimated fair value is €190 based on 2 Stage Free Cash Flow to Equity Aurubis is estimated to be...

If you are wondering whether Bayer at around €38.00 is still offering value after a strong run, this article will walk through what the current price actually reflects. Bayer's share price shows a mixed return profile, with a 4.4% move over 7 days, 14.1% over 30 days, 93.6% over 1 year, and longer term returns of a 23.0% decline over 3 years and a 16.0% decline over 5 years. Recent news around Bayer has focused on its ongoing portfolio and restructuring efforts as well as continued attention...

As the European markets continue to thrive, with the STOXX Europe 600 Index reaching new highs and closing 2025 with impressive gains, investors are increasingly looking for opportunities within this robust economic environment. In such a context, identifying stocks that may be trading below their intrinsic value can provide potential avenues for growth, particularly when these stocks are supported by strong fundamentals and positive market conditions.